findmyKOL

Corey Langer, MD

Enriched profile

Director of Thoracic Oncology and Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania · University of Pennsylvania

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Philadelphia, PA · Northeast · United StatesSpecialtyHematology / OncologyFocusLung Cancer Treatments and Mutations+4
Active KOLfindmyKOL type: EliteLatest publication2024Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Corey Langer is Director of Thoracic Oncology and Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania at University of Pennsylvania. OpenAlex indexes 865 publications with 40,136 citations (h-index 90); ClinicalTrials.gov lists 25 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 14 Oct 2026

Corey Langer, MD, is Director of Thoracic Oncology and Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania at University of Pennsylvania – Perelman School of Medicine / Abramson Cancer Center. The public record shows 865 publications with 40,136 citations (h-index 90), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies. It also documents an investigator role on 25 registered clinical trials, industry payments reported by 38 companies.

  • Most recent indexed publication: 2024 · The oncologist
  • Top research focus: Lung Cancer Treatments and Mutations
  • 25 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 38 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)13 trialsHead & Neck Cancer7 trialsSmall Cell Lung Carcinoma4 trialsMesothelioma2 trialsMesothelioma, Malignant1 trialLymphoma1 trialCarcinoma, Squamous Cell1 trialSalivary Gland Neoplasms1 trialCarcinoma, Verrucous1 trial

Research focus

OpenAlex concept fingerprint
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research StudiesCancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials—Industry payments36Publications3Alunbriggeneric · BrigatinibClinical trials—Industry payments1Publications2Libtayogeneric · CemiplimabClinical trials—Industry payments22Publications—Zepzelcageneric · LurbinectedinClinical trials—Industry payments15Publications—Rybrevantgeneric · AmivantamabClinical trials—Industry payments13Publications—Tecentriqgeneric · AtezolizumabClinical trials—Industry payments10Publications—Enhertugeneric · TrastuzumabClinical trials—Industry payments9Publications—Alecensageneric · AlectinibClinical trials—Industry payments8Publications—Imfinzigeneric · DurvalumabClinical trials—Industry payments7Publications—Firdapsegeneric · AmifampridineClinical trials—Industry payments6Publications—Tagrissogeneric · OsimertinibClinical trials—Industry payments4Publications—Cabometyxgeneric · CabozantinibClinical trials—Industry payments3Publications—

Works with

trial sponsors and companies reporting payments
Merck Sharp & Dohme LLCClinical trials—Industry payments59Novocure Inc.Clinical trials—Industry payments17AstraZeneca Pharmaceuticals LPClinical trials—Industry payments16Genentech USA, Inc.Clinical trials—Industry payments16Jazz Pharmaceuticals Inc.Clinical trials—Industry payments16Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments13Janssen Biotech, Inc.Clinical trials—Industry payments10Fox Chase Cancer CenterClinical trials9Industry payments—Amgen Inc.Clinical trials—Industry payments7Daiichi Sankyo Inc.Clinical trials—Industry payments7Genzyme CorporationClinical trials—Industry payments7AstraZeneca UK LimitedClinical trials—Industry payments6Catalyst Pharmaceuticals, Inc.Clinical trials—Industry payments6Gilead Sciences, Inc.Clinical trials—Industry payments6Eastern Cooperative Oncology GroupClinical trials5Industry payments—Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments5Janssen Research & Development, LLCClinical trials—Industry payments4Novartis Pharmaceuticals CorporationClinical trials—Industry payments4Abramson Cancer Center at Penn MedicineClinical trials3Industry payments—Exelixis Inc.Clinical trials—Industry payments3Janssen Scientific Affairs, LLCClinical trials—Industry payments3Merck Sharp & Dohme CorporationClinical trials—Industry payments3Bayer Healthcare Pharmaceuticals Inc.Clinical trials—Industry payments2Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments2Eli Lilly and CompanyClinical trials—Industry payments2GlaxoSmithKline, LLC.Clinical trials—Industry payments2Lilly USA, LLCClinical trials—Industry payments2Radiation Therapy Oncology GroupClinical trials2Industry payments—SWOG Cancer Research NetworkClinical trials2Industry payments—Taiho Oncology, Inc.Clinical trials—Industry payments2

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
865publications

Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.

40,136citations

Total citations across indexed works.

90h-index

Hirsch index (OpenAlex). i10-index 337.

Clinical & industry

trials, payments and federal funding
25clinical trials

Investigator role on registered studies.

View trials ↓
38companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 25 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 14 Oct 2026

38 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    41.3%
    Corticosteroid32.6%
    Prednisone100%
    Part D≥37 patients
    Serotonin-3 Receptor Antagonist8.7%
    Ondansetron Hcl100%
    Part D≥12 patients
  • Anti-infectives

    19.3%
    Macrolide Antimicrobial11.5%
    Azithromycin100%
    Part D≥21 patients
    Penicillins with extended spectrum7.8%
    Amoxicillin-Clavulanate Potass100%
    Part D≥15 patients
  • Nervous system

    12.4%
    Gabapentinoids7.3%
    Gabapentin100%
    Part D<11 patients
    Benzodiazepine5%
    Alprazolam100%
    Part D<11 patients
All 6 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 14 Oct 2026

192 congress contributions (2003–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Roger B. Cohen161Charu Aggarwal126Joshua Bauml97Christine Ciunci82Tracey L. Evans81Benjamin Movsas74Melina E. Marmarelis62Jeffrey C. Thompson60Evan Alley55Anil Vachani54Keith A. Cengel52Erica L. Carpenter49Aditi P. Singh49Wei‐Ting Hwang48Charles B. Simone46James Stevenson45Steven J. Feigenberg43Scott Gettinger42Abigail T. Berman42D. Ross Camidge42Walter J. Curran41Mark A. Socinski40Lova Sun39Stephen Bagley36John A. Kosteva36Hossein Borghaei35Charų C. Aggarwal35Ramesh Rengan34Stephanie S. Yee34Ritsuko Komaki34David Kerstein33William P. Levin31Luis Paz‐Ares31John A. Ridge30Joan H. Schiller28Sharyn I. Katz28Steven Μ. Albelda24Susan Stonehouse-Lee24Shirish M. Gadgeel24Victoria Sherry24

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/corey-langer-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • Other

    iaslc.org/iaslc-news/lung-cancer-considered/conversation-thoracic-oncologist-dr-corey-langer

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Medical Oncology

    1987
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
  • Board Certified

    Hematology

    1986
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
  • Board Certified

    Internal Medicine

    1984
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
  • MD

    Boston University School of Medicine

    1981
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗

Editorial & leadership roles

journal and society appointments
  • Editor-in-Chief

    IASLC Lung Cancer News

    2016
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗
  • Fellow

    American College of Physicians (FACP)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗
  • Member

    HUP Pharmacy and Therapeutics Committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
  • Member

    CAR-T Cell Data Safety Monitoring Committee, University of Pennsylvania

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
  • Co-Chair

    Medical Oncology Committee, NRG Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesotheliomahope.com ↗
  • Member

    Core Thoracic Committee, ECOG

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesotheliomahope.com ↗
  • Member

    American Society of Clinical Oncology (ASCO)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesotheliomahope.com ↗
  • Member

    American Association for Cancer Research (AACR)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesotheliomahope.com ↗
  • Member

    International Association for the Study of Lung Cancer (IASLC)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesotheliomahope.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.